178 related articles for article (PubMed ID: 397063)
1. Treatment of gram-negative bacteremia with antiserum to core glycolipid. I. The experimental basis of immunity to endotoxin.
Ziegler EJ; McCutchan JA; Braude AI
Eur J Cancer (1965); 1979; 15 Suppl():71-6. PubMed ID: 397063
[No Abstract] [Full Text] [Related]
2. Treatment of gram-negative bacteremia with antiserum to core glycolipid II. A controlled trial of antiserum in patients with bacteremia.
McCutchan JA; Ziegler EJ; Braude AI
Eur J Cancer (1965); 1979; 15 Suppl():77-80. PubMed ID: 397064
[No Abstract] [Full Text] [Related]
3. Antiserum treatment of gram-negative bacteremia.
Braude AI; Ziegler EJ; McCutchan JA
Schweiz Med Wochenschr; 1978 Dec; 108(48):1872-6. PubMed ID: 362528
[TBL] [Abstract][Full Text] [Related]
4. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli.
Ziegler EJ; McCutchan JA; Fierer J; Glauser MP; Sadoff JC; Douglas H; Braude AI
N Engl J Med; 1982 Nov; 307(20):1225-30. PubMed ID: 6752708
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of human gram-negative bacteremia with antiserum against endotoxin core.
Ziegler EJ; McCutchan JA; Douglas H; Braude AI
Trans Assoc Am Physicians; 1981; 94():39-43. PubMed ID: 7046193
[No Abstract] [Full Text] [Related]
6. [Anti-endotoxin core glycolipid antibody: the preparation of immune serum of E. Coli J5].
Xu XN; Li ZJ; Li YP
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2004 Jun; 16(6):358-60. PubMed ID: 15182450
[TBL] [Abstract][Full Text] [Related]
7. Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms.
Opal SM; Palardy JE; Chen WH; Parejo NA; Bhattacharjee AK; Cross AS
J Infect Dis; 2005 Dec; 192(12):2074-80. PubMed ID: 16288370
[TBL] [Abstract][Full Text] [Related]
8. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
Calandra T; Baumgartner JD; Glauser MP
Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
[TBL] [Abstract][Full Text] [Related]
9. Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core.
Pollack M; Huang AI; Prescott RK; Young LS; Hunter KW; Cruess DF; Tsai CM
J Clin Invest; 1983 Dec; 72(6):1874-81. PubMed ID: 6358257
[TBL] [Abstract][Full Text] [Related]
10. Anticore endotoxin F(ab')2 equine immunoglobulin fragments protect against lethal effects of gram-negative bacterial sepsis.
Dunn DL; Mach PA; Condie RM; Cerra FB
Surgery; 1984 Aug; 96(2):440-6. PubMed ID: 6379963
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of Re-LPS antiserum on experimental multiple system organ failure.
Yao YM; Tian HM; Wang YP; Sheng ZY; Shi ZG; Xu SH
Chin Med J (Engl); 1992 Oct; 105(10):833-8. PubMed ID: 1291201
[TBL] [Abstract][Full Text] [Related]
12. Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis.
Cross AS; Opal SM; Warren HS; Palardy JE; Glaser K; Parejo NA; Bhattacharjee AK
J Infect Dis; 2001 Apr; 183(7):1079-86. PubMed ID: 11237833
[TBL] [Abstract][Full Text] [Related]
13. Antibody to cell wall glycolipid of Gram-negative bacteria: induction of immunity to bacteremia and endotoxemia.
Braude AI; Ziegler EJ; Douglas H; McCutchan JA
J Infect Dis; 1977 Aug; 136 Suppl():S167-73. PubMed ID: 330776
[TBL] [Abstract][Full Text] [Related]
14. Human antiserum for prevention of the local shwartzman reaction and death from bacterial lipopolysaccharides.
Ziegler EJ; Douglas H; Braude AI
J Clin Invest; 1973 Dec; 52(12):3236-8. PubMed ID: 4584346
[TBL] [Abstract][Full Text] [Related]
15. Immunological intervention in endotoxin shock.
Ziegler EJ
Prog Clin Biol Res; 1988; 272():319-25. PubMed ID: 3293079
[No Abstract] [Full Text] [Related]
16. Use of mucin and hemoglobin in experimental murine gram-negative bacteremia enhances the immunoprotective action of antibodies reactive with the lipopolysaccharide core region.
Appelmelk BJ; Verwey-van Vught AM; Maaskant JJ; Schouten WF; Thijs LG; Maclaren DM
Antonie Van Leeuwenhoek; 1986; 52(6):537-42. PubMed ID: 3545072
[TBL] [Abstract][Full Text] [Related]
17. Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis.
Cross AS; Opal S; Cook P; Drabick J; Bhattacharjee A
Vaccine; 2004 Feb; 22(7):812-7. PubMed ID: 15040932
[TBL] [Abstract][Full Text] [Related]
18. [Protective effect of antiserum to Re-LPS on experimental multiple organ failure].
Yao YM
Zhonghua Wai Ke Za Zhi; 1992 Apr; 30(4):244-7, 256. PubMed ID: 1473411
[TBL] [Abstract][Full Text] [Related]
19. Functional role of antibody against "core" glycolipid of Enterobacteriaceae.
Young LS; Stevens P; Ingram J
J Clin Invest; 1975 Oct; 56(4):850-61. PubMed ID: 1099119
[TBL] [Abstract][Full Text] [Related]
20. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
Gorelick KJ; Chmel H
Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
